Hey there! I'm a subscriber to the newsletter. I have been a user of peptides for some time now, specifically BPC-157, TB-500, Selank. As such, I've been exposed to Cerebrolysin. Most of my fellow peptide travelers look at it with a healthy degree of suspicion. It sounds more like a witches brew. The science is indeed sketch.
However, I wanted to make some (referenced :) ) corrections to your analysis. I think the general thrust of my argument is this - there seems to be emerging science about small-chain active peptides. These exhibit different stability and transport characteristics than larger proteins. There might be mechanism of action here that you're not considering.
Hey there! I'm a subscriber to the newsletter. I have been a user of peptides for some time now, specifically BPC-157, TB-500, Selank. As such, I've been exposed to Cerebrolysin. Most of my fellow peptide travelers look at it with a healthy degree of suspicion. It sounds more like a witches brew. The science is indeed sketch.
However, I wanted to make some (referenced :) ) corrections to your analysis. I think the general thrust of my argument is this - there seems to be emerging science about small-chain active peptides. These exhibit different stability and transport characteristics than larger proteins. There might be mechanism of action here that you're not considering.
- BDNF
... (read 533 more words →)